Virax Biolabs Announces Exercise of Preferred Investment Options for $3.3 Million in Proceeds
Virax Biolabs Group Limited (Nasdaq: VRAX) announced that it has exercised preferred investment options to raise approximately $3.3 million before fees and expenses, by issuing up to 548,000 ordinary shares at a reduced price of $6 per share.
Topics: capital raising preferred investment options warrants exercise